Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HCWB | US
-0.01
-3.37%
Healthcare
Biotechnology
30/06/2024
13/04/2026
0.35
0.36
0.37
0.34
HCW Biologics Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing novel immunotherapies for chronic low-grade inflammation and age-related diseases. The company's lead products include HCW9218 which is an injectable immunotherapeutic for patients with pancreatic ovarian breast prostate and colorectal cancers as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases such as alopecia areata and metabolic diseases. It also develops HCW9201 a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar Florida.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
171.4%1 month
353.4%3 months
217.4%6 months
171.8%-
-
2.80
-1.59
0.37
-3.63
7.66
-
-36.58M
15.37M
15.37M
-
-2.24K
-
-0.60
-344.32
0.87
0.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.15
Range1M
0.92
Range3M
1.40
Rel. volume
0.02
Price X volume
169.98K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.5 | 16.74M | -4.51% | n/a | 10.72% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.63 | 16.17M | 3.14% | n/a | 54.59% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 1.12 | 16.08M | -3.45% | n/a | 11.72% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.576 | 15.58M | 2.78% | n/a | 1.90% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.74 | 15.53M | -0.57% | n/a | 0.00% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.98 | 15.49M | 7.69% | n/a | 1.41% |
| DarT Bioscience Inc | DARE | Biotechnology | 1.78 | 15.21M | -2.73% | 0.12 | 218.34% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.43 | 14.55M | 14.40% | n/a | 10.24% |
| NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 0.7108 | 14.08M | 1.54% | n/a | -2.11% |
| JSPR | JSPR | Biotechnology | 0.919 | 13.88M | 14.55% | n/a | 2.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.63 | 0.53 | Cheaper |
| Ent. to Revenue | 7.66 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.80 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 217.37 | 72.80 | Riskier |
| Debt to Equity | -1.59 | -1.23 | Cheaper |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 15.37M | 3.66B | Emerging |